Drug
Axs 12
Axs 12: highest development phase Phase 3, developed by Axsome Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Axsome Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AXS-12 (reboxetine) NCT05059223 | Phase 3 | Narcolepsy |
| AXS-12 (reboxetine) NCT05113745 | Phase 3 | Narcolepsy |
| AXS-12 (Reboxetine) NCT03881852 | Phase 2 | Narcolepsy |
Latest
No recent events.
Follow Axs 12 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.